PetCaseFinder

Peer-reviewed veterinary case report

Problems with blood tests for diagnosing canine leishmaniasis in dogs

By Santarém, Nuno et al.·Published in Scientific reports·2020·Instituto de Investiga&#xe7·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Challenges in the serological evaluation of dogs clinically suspect for canine leishmaniasis.

Species:
dog

Plain-English summary

A group of dogs suspected of having canine leishmaniasis (a disease caused by parasites that can affect both dogs and humans) underwent various blood tests to check for the infection. Researchers found that half of the test results were inconclusive, meaning some dogs tested positive while others tested negative, which can lead to misdiagnosis. They suggested that using a new method to analyze the test results could help improve the accuracy of diagnosing this disease. Better testing could lead to more effective treatment and management of canine leishmaniasis, ultimately protecting both dogs and people from the disease.

People also search for: dog leishmaniasis symptoms · how to test for leishmaniasis in dogs · canine leishmaniasis treatment options

Abstract

Canine leishmaniasis is a major veterinary issue and also a public health challenge due to its zoonotic potential. In this context, serological evaluation is essential for Canine leishmaniasis management. Several serological alternatives, such as rapid diagnostic tests, enzyme-linked immunosorbent assay (ELISA) and immunofluorescence antibody test (IFAT), are well established. In fact, the capacity of distinct tests and antigens, evaluated by their sensitivity and specificity, to detect disease is normally considered sufficient for diagnosing Canine leishmaniasis. In this context, we evaluated the seropositivity using 8 different serological tests (ELISA with Leishmania recombinant proteins (rK39, LicTXNPx); soluble promastigote Leishmania antigens (SPLA); commercial ELISA test) in 82 clinically suspect animals from Northern Portugal. The obtained serological data originated 50% of inconclusive serological information with a mixture of seropositive and seronegative results for individual animals. Cut-off independent risk groups were then generated from the serological data to evaluate the clustering of the samples. This analysis originated risk groups that correlated with the most seropositive samples, suggesting that this method might be used, in a cut-off independent manner, to improve conventional serological evaluation. Ultimately, given that no test prioritization exists, the use of any single serological test increases the potential for misdiagnosis, along with all associated risks for the dog as well as public health. The use of a cut-off independent analysis has the potential to improve the predictive values of these tests, enabling a more accurate evaluation of the dog's condition.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/32080327/